Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia

Journal of Neurophysiology

Volumn 115, Issue 3, 2016, Pages 1713-1729

  Tamtè, Martin ^a   Brys, Ivani ^a   Richter, Ulrike ^a   Ivica, Nedjeljka ^a   Halje, Pär ^a   Petersson, Per ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Levodopa; Parkinson s disease; Systems neurophysiology

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DYSKINESIA; FEMALE; FREQUENCY ANALYSIS; LEVODOPA-INDUCED DYSKINESIA; NEUROPHYSIOLOGICAL MONITORING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; DEVICES; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN WAVES; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DRUG EVALUATION, PRECLINICAL; DYSKINESIA, DRUG-INDUCED; ELECTROENCEPHALOGRAPHY; FEMALE; LEVODOPA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84984794064     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00868.2015     Document Type: Article

References (76)

1. Alam M, Capelle HH, Schwabe K, Krauss JK. Effect of deep brain stimulation on levodopa-induced dyskinesias and striatal oscillatory local field potentials in a rat model of Parkinson’s disease. Brain Stimul 7: 13-20, 2013.
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375, 1989.
3. Alegre M, López-Azcárate J, Alonso-Frech F, Rodríguez-Oroz MC, Valencia M, Guridi J, Artieda J, Obeso JA. Subthalamic activity during diphasic dyskinesias in Parkinson’s disease. Mov Disord 27: 1178-1181, 2012.
4. Alonso-Frech F, Zamarbide I, Alegre M, Rodríguez-Oroz MC, Guridi J, Manrique M, Valencia M, Artieda J, Obeso JA. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson’s disease. Brain 129: 1748-1757, 2006.
5. Avila I, Parr-Brownlie LC, Brazhnik E, Castañeda E, Bergstrom DA, Walters JR. Beta frequency synchronization in basal ganglia output during rest and walk in a hemiparkinsonian rat. Exp Neurol 221: 307-319, 2010.
6. Barthó P, Hirase H, Monconduit L, Zugaro M, Harris KD, Buzsáki G. Characterization of neocortical principal cells and interneurons by network interactions and extracellular features. J Neurophysiol 92: 600-608, 2004.
7. Berger H. Über das Elektroenkephalogramm des Menschen. Arch Psychiatr Nervenkr 87: 527-570, 1929.
8. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507-520, 1994.
9. Berke JD, Okatan M, Skurski J, Eichenbaum HB. Oscillatory entrainment of striatal neurons in freely moving rats. Neuron 43: 883-896, 2004.
10. Brazhnik E, Novikov N, McCoy AJ, Cruz AV, Walters JR. Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats. Exp Neurol 261: 563-577, 2014.
11. Breger LS, Dunnett SB, Lane EL. Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiol Dis 50: 142-150, 2013.
12. Breit S, Martin A, Lessmann L, Cerkez D, Gasser T, Schulz JB. Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6-hydroxydopamine rat model. J Neurosci Res 86: 1388-1396, 2008.
13. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson’s disease. Mov Disord 18: 357-363, 2003.
14. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s disease. J Neurosci 21: 1033-1038, 2001.
15. Brücke C, Huebl J, Schönecker T, Neumann WJ, Yarrow K, Kupsch A, Blahak C, Lütjens G, Brown P, Krauss JK, Schneider GH, Kühn AA. Scaling of movement is related to pallidal γ oscillations in patients with dystonia. J Neurosci 32: 1008-1019, 2012.
16. Cagnan H, Kuhn AA, Brown P. Co-modulation of finely tuned high-gamma band activity across hemispheres in Parkinson’s disease. Clin Neurophysiol 125: 777-785, 2014.
17. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130: 1819-1833, 2007.
18. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96: 1718-1727, 2006.
19. Cassidy M, Mazzone P, Oliviero A, Insola A, Tonali P, Di Lazzaro V, Brown P. Movement-related changes in synchronization in the human basal ganglia. Brain 125: 1235-1246, 2002.
20. Chen L, Qi R, Chen XY, Xue Y, Xu R, Wei HJ. Modulation of the activity of globus pallidus by dopamine D1-like receptors in parkinsonian rats. Neuroscience 194: 181-188, 2011.
21. Coppola G, Arcieri S, D’Aniello A, Messana T, Verrotti A, Signoriello G, Pascotto A. Levetiracetam in submaximal subcutaneous pentylentetrazolinduced seizures in rats. Seizure 19: 296-299, 2010.
22. Costa RM, Lin SC, Sotnikova TD, Cyr M, Gainetdinov RR, Caron MG, Nicolelis MA. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 52: 359-369, 2006.
23. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst Rev 2: CD003467, 2003.
24. de Hemptinne C, Swann NC, Ostrem JL, Ryapolova-Webb ES, San Luciano M, Galifianakis NB, Starr PA. Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson’s disease. Nat Neurosci 18: 779-786, 2015.
25. Delaville C, Cruz AV, McCoy AJ, Brazhnik E, Avila I, Novikov N, Walters JR. Oscillatory activity in basal ganglia and motor cortex in an awake behaving rodent model of Parkinson’s disease. Basal Ganglia 3: 221-227, 2014.
26. Dupre KB, Cruz AV, Gerber CM, Eyring KW, Walters JR. High gamma cortical activity in the development of L-dopa-induced dyskinesia in a rodent model of Parkinson’s disease (Abstract). In: Society for Neuroscience 2013. San Diego, CA: Halls B-H, November 12, 2013, 648.01/QQ25.
27. Finkbeiner S, Frumkin M, Kassner PD. Cell-based screening: extracting meaning from complex data. Neuron 86: 160-174, 2015.
28. Fuentes R, Petersson P, Nicolelis MA. Restoration of locomotive function in Parkinson’s disease by spinal cord stimulation: mechanistic approach. Eur J Neurosci 32: 1100-1108, 2010.
29. Fuentes R, Petersson P, Siesser WB, Caron MG, Nicolelis MA. Spinal cord stimulation restores locomotion in animal models of Parkinson’s disease. Science 323: 1578-1582, 2009.
30. Gage GJ, Stoetzner CR, Wiltschko AB, Berke JD. Selective activation of striatal fast-spiking interneurons during choice execution. Neuron 67: 466-479, 2010.
31. Gervasoni D, Lin SC, Ribeiro S, Soares ES, Pantoja J, Nicolelis MA. Global forebrain dynamics predict rat behavioral states and their transitions. J Neurosci 24: 11137-11147, 2004.
32. Gilmour TP, Lieu CA, Nolt MJ, Piallat B, Deogaonkar M, Subramanian T. The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys. Exp Neurol 228: 53-58, 2011.
33. Gioanni Y, Lamarche M. A reappraisal of rat motor cortex organization by intracortical microstimulation. Brain Res 344: 49-61, 1985.
34. Goldberg JA, Boraud T, Maraton S, Haber SN, Vaadia E, Bergman H. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson’s disease. J Neurosci 22: 4639-4653, 2002.
35. Goldberg JA, Rokni U, Boraud T, Vaadia E, Bergman H. Spike synchronization in the cortex/basal-ganglia networks of Parkinsonian primates reflects global dynamics of the local field potentials. J Neurosci 24: 6003-6010, 2004.
36. González-Hernández T, Barroso-Chinea P, Rodríguez M. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat. Mov Disord 19: 1029-1042, 2004.
37. Graul AI. Promoting, improving and accelerating the drug development and approval processes. Drug News Perspect 22: 30-38, 2008.
38. Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P. Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci 32: 16541-16551, 2012.
39. Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson’s disease: networks, models and treatments. Trends Neurosci 30: 357-364, 2007.
40. Harris KD, Henze DA, Csicsvari J, Hirase H, Buzsáki G. Accuracy of tetrode spike separation as determined by simultaneous intracellular and extracellular measurements. J Neurophysiol 84: 401-414, 2000.
41. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 65: 171-222, 2013.
42. Ivica N, Tamté M, Ahmed M, Richter U, Petersson P. Design of a high-density multi-channel electrode for multi-structure parallel recordings in rodents. Conf Proc IEEE Eng Med Biol Soc 2014: 393-396, 2014.
43. Jacobs BL. Effect of two dopamine receptor blockers on a serotonin-mediated behavioral syndrome in rats. Eur J Pharmacol 27: 363-366, 1974.
44. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76: 1346-1353, 2001.
45. Kish LJ, Palmer MR, Gerhardt GA. Multiple single-unit recordings in the striatum of freely moving animals: effects of apomorphine and D-amphetamine in normal and unilateral 6-hydroxydopamine-lesioned rats. Brain Res 833: 58-70, 1999.
46. Kreiss DS, Mastropietro CW, Rawji SS, Walters JR. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson’s disease. J Neurosci 17: 6807-6819, 1997.
47. Kühn AA, Tsui A, Aziz T, Ray N, Brücke C, Kupsch A, Schneider GH, Brown P. Pathological synchronisation in the subthalamic nucleus of patients with Parkinson’s disease relates to both bradykinesia and rigidity. Exp Neurol 215: 380-387, 2009.
48. Lalo E, Thobois S, Sharott A, Polo G, Mertens P, Pogosyan A, Brown P. Patterns of bidirectional communication between cortex and basal ganglia during movement in patients with Parkinson disease. J Neurosci 28: 3008-3016, 2008.
49. Lehew G, Nicolelis MA. State-of-the-art microwire array design for chronic neural recordings in behaving animals. In: Methods for Neural Ensemble Recordings (2nd ed.), edited by Nicolelis MA. Boca Raton, FL: CRC Press/Taylor & Francis, 2008, chapt. 1, p. 1-20.
50. Levy R, Hutchison WD, Lozano AM, Dostrovsky JO. High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor. J Neurosci 20: 7766-7775, 2000.
51. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15: 120-132, 2002.
52. Mitra P, Bokil H. Observed Brain Dynamics. Oxford, UK; New York: Oxford Univ. Press, 2008.
53. Nadjar A, Gerfen CR, Bezard E. Priming for L-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Prog Neurobiol 87: 1-9, 2009.
54. Neafsey EJ, Sievert C. A second forelimb motor area exists in rat frontal cortex. Brain Res 232: 151-156, 1982.
55. Nini A, Feingold A, Slovin H, Bergman H. Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J Neurophysiol 74: 1800-1805, 1995.
56. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci 23: S117-S126, 2000.
57. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. Eur J Neurol 19: 155-162, 2012.
58. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter:treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66: 983-995, 2006.
59. Palmér T, Tamtè M, Halje P, Enqvist O, Petersson P. A system for automated tracking of motor components in neurophysiological research. J Neurosci Methods 205: 334-344, 2012.
60. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Amsterdam; Boston, MA: Academic Press/Elsevier, 2007.
61. PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. Longterm effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384: 1196-1205, 2014.
62. Peixoto MF, Araujo NP, Silva RH, Castro JP, Fukushiro DF, Faria RR, Zanier-Gomes PH, Medrano WA, Frussa-Filho R, Abílio VC. Effects of gabaergic drugs on reserpine-induced oral dyskinesia. Behav Brain Res 160: 51-59, 2005.
63. Pesaran B. Neural signal processing: quantitative analysis of neural activity. Short course III, presented at 2008 Society for Neuroscience Annual Meeting, edited by Mitra PP. Washington, DC: November 15-19, 2008, p. 1-12.
64. Pourcher E, Bonnet AM, Kefalos J, Dubois B, Agid Y. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson’s disease. Mov Disord 4: 195-201, 1989.
65. Santana M, Palmér T, Simplício H, Fuentes R, Petersson P. Characterization of long-term motor deficits in the 6-OHDA model of Parkinson’s disease in the common marmoset. Behav Brain Res 290: 90-101, 2015.
66. Santana MB, Halje P, Simplício H, Richter U, Freire MA, Petersson P, Fuentes R, Nicolelis MA. Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease. Neuron 84: 716-722, 2014.
67. Sharott A, Magill PJ, Harnack D, Kupsch A, Meissner W, Brown P. Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. Eur J Neurosci 21: 1413-1422, 2005.
68. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 26: 264-270, 2011.
69. Stein E, Bar-Gad I. Beta oscillations in the cortico-basal ganglia loop during parkinsonism. Exp Neurol 245: 52-59, 2013.
70. Svenningsson P, Rosenblad C, af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H. Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson’s disease: a dosefinding study. Brain 138: 963-973, 2015.
71. Tai CH, Boraud T, Bezard E, Bioulac B, Gross C, Benazzouz A. Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J 17: 1820-1830, 2003.
72. Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, Gardoni F, Carta M. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease. Neuroscience 265: 245-252, 2014.
73. Wang Y, Zhang QJ, Liu J, Ali U, Gui ZH, Hui YP, Chen L, Wu ZH, Li Q. Noradrenergic lesion of the locus coeruleus increases apomorphineinduced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson’s disease. Brain Res 1310: 189-199, 2010.
74. West MO, Carelli RM, Pomerantz M, Cohen SM, Gardner JP, Chapin JK, Woodward DJ. A region in the dorsolateral striatum of the rat exhibiting single-unit correlations with specific locomotor limb movements. J Neurophysiol 64: 1233-1246, 1990.
75. Winkler C, Kirik D, Björklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10: 165-186, 2002.
76. Wolz M, Löhle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grählert X, Schwarz J, Storch A. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebocontrolled trial. J Neural Transm 117: 1279-1286, 2010.